首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Inhibition of chronic rejection by antibody induced vascular accommodation in fully allogeneic heart allografts.
【24h】

Inhibition of chronic rejection by antibody induced vascular accommodation in fully allogeneic heart allografts.

机译:在完全同种异体心脏同种异体移植物中,抗体诱导的慢性血管抑制可抑制慢性排斥。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

BACKGROUND: The potential role of altered antibody responses as an effector protective mechanism to induce graft accommodation has been widely investigated in xenogeneic responses. Here we investigate the protective effects of antibody binding to vascular endothelium in a fully mismatched allogeneic model of heart transplantation. METHODS: ACI recipients of WF cardiac grafts were treated either with allochimeric [alpha1h ]-RT1.A class I major histocompatibility complex (MHC) extracts (1 mg/rat, p.v. day 0) or high dose of CsA (10 mg/kg/day, p.o., day 0-6). Cardiac allografts were evaluated at 100 days posttransplant by immunohistology for evidence of chronic rejection and/or vascular accommodation. Activation of apoptotic or antiapoptotic mechanisms was verified by DNA fragmentation (TUNEL) analysis. RESULTS: Allochimeric therapy resulted in inhibition of chronic rejection, absence of neointimal formation and induction of vascular accommodation of fully allogeneic WF hearts in ACI hosts. Such accommodation was evident by IgG and IgM vascular endothelial binding and marked reduction of DNA fragmentation. In contrast, CsA therapy resulted in marked neointimal proliferation, without evidence of vascular accommodation. Immunohistochemical analysis failed to demonstrate vascular endothelial antibody binding. Further, severe chronic rejection following CsA treatment was accompanied by marked DNA fragmentation. CONCLUSION: Alteration of humoral immunity induces vascular accommodation in allogeneic transplantation. Vascular accommodation is the underlying mechanism for inhibition allograft vasculopathy following allochimeric MHC class I therapy.
机译:背景:在异种反应中,已广泛研究了改变的抗体反应作为诱导移植物适应的效应子保护机制的潜在作用。在这里,我们研究了在完全不匹配的心脏移植同种异体模型中抗体与血管内皮结合的保护作用。方法:用同种异体的[α1h] -RT1处理WF心脏移植的ACI接受者。I类主要组织相容性复合物(MHC)提取物(1 mg /大鼠,pv第0天)或高剂量的CsA(10 mg / kg /天,po,第0-6天)。在移植后第100天,通过免疫组织学评估心脏同种异体移植是否具有慢性排斥和/或血管适应性的证据。凋亡或抗凋亡机制的激活通过DNA片段分析(TUNEL)进行了验证。结果:同种异体嵌合疗法可抑制ACI宿主慢性排斥反应,新内膜形成的缺乏以及诱导完全异基因WF心脏的血管适应。通过IgG和IgM血管内皮结合以及DNA片段的显着减少,可以证明这种调节。相反,CsA疗法导致明显的新内膜增生,而没有血管调节的迹象。免疫组织化学分析未能证明血管内皮抗体结合。此外,CsA治疗后严重的慢性排斥反应伴有明显的DNA断裂。结论:体液免疫力的改变可引起异体移植血管的适应。血管调节是抑制同种异体MHC I类治疗后同种异体移植血管病变的潜在机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号